UTIs are common bladder infections that primarily affect women without underlying health conditions. About half of all women will experience a UTI at least once in their lifetime, and 30% may face recurring infections. Treating these recurrences can be difficult when traditional antibiotics fail due to antibiotic resistance, which emphasizes the need for new treatment options.
 |
| Medical Learner |
Key Points:
• FDA Approval: The FDA has approved a new antibiotic, Blujepa (gepotidacin), for uncomplicated urinary tract infections (UTIs) in women and girls aged 12 or older.
• First in Nearly 30 Years: It’s the first oral antibiotic for UTIs approved in nearly three decades.
• Dual-Action Mechanism: Blujepa works by blocking two key enzymes bacteria need to grow, which helps prevent antibiotic resistance.
• Mild Side Effects: The most common side effects are diarrhea and nausea.
• Government Support: Blujepa’s development was partially funded by U.S. government agencies, including the Biomedical Advanced Research and Development Authority and the Defense Threat Reduction Agency.
• Availability: The drug is expected to be available in the U.S. by the second half of this year.
The U.S. Food and Drug Administration (FDA) has approved a new antibiotic, Blujepa (gepotidacin), to treat uncomplicated urinary tract infections (UTIs) in women and girls aged 12 or older. This is the first oral antibiotic for UTIs approved in nearly 30 years.
Blujepa works by blocking two key enzymes that bacteria need to grow and multiply. This unique dual-targeted approach makes it more difficult for bacteria to quickly develop resistance, offering a promising solution for infections that no longer respond to standard antibiotics.
The side effects of Blujepa are mild, with the most common being diarrhea and nausea. The development of the medication was partially supported by the U.S. government, specifically through grants from the Biomedical Advanced Research and Development Authority and the Defense Threat Reduction Agency.
Blujepa is expected to be available in the U.S. in the second half of this year, providing a new option for those suffering from UTIs.
SOURCE:
Blujepa (gepotidacin) approved by US FDA for treatment of uncomplicated urinary tract infections (uUTIs) in female adults and paediatric patients 12 years of age and older.
Read More on our Website medicallearnerrs.blogspot.com, Medicallearner, Medical Learner
0 Comments